Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/780366

Contents of this Issue

Navigation

Page 26 of 47

www.clinicalomics.com January/February 2017 Clinical OMICs 25 because of the growing challenge of antibiotic resistance, it is clear that there is a need for new antibiotic drugs." Keeping an Eye on the Target The promise of translation research has always been to transform laboratory techniques into clinical modalities. Genomics transcends the translational path by helping sci- entists address the needs of patients, from the development of new molecular diagnostics for improving disease prog- nosis to pharmacogenomic analyses that identify genetic background incompatible with various drug therapies. "All of us now carry resistance genes in our gut bacte- ria, and knowing which ones we carry could help to better target antibiotic therapies," said Dr. Gillings. "I see a time where all patients are subject to routine genome screening both of isolates and their total microbiota to identify resis- tance genes prior to treatment." Dr. Jaing agreed, adding that "it will be really helpful to have rapid point-of-care diagnostic tests to determine someone's current gut bacterial antibiotic resistance profile before an antibiotic is prescribed." Additionally, investigators from multiple disciplines are beginning to team up under the umbrella of systems biology to create novel computational approaches that incorporate multiple omics data (proteomics, metabolomics, transcrip- tomics, etc.), in order to construct predictive models that help explain human antibiotic resistance. "As genomics, informatics, and computational technolo- gies continue to be developed and become more ubiquitous in clinical and even personal healthcare, we are looking for- ward to new opportunities that bolster our mission to sup- port basic and applied research to better understand, treat and, ultimately prevent infectious diseases, and in this case those from antibiotic-resistant bacteria," OGAT members concluded. Genomics has opened up avenues of research that could hardly be envisioned when genome mapping projects began so many years ago. However, its service to protecting public health was on many researchers wish lists from the start. Technological advances that are starting to see more frequent use, such as nanopore sequencing and long-read sequencing technology, will only serve to embolden scientists to create more efficient therapies that could one day make concepts like resistance a distant memory. Although, until that day comes, scientist, clinicians, and the public need to stay vigi- lant and informed to make certain that Alexander Fleming's prognostication doesn't become real for every antibiotic therapy we develop. @ WEEKLY The hottest industry news and analyses on research, tools, and applications impacting the implementation of omics technologies in the clinic ClinicalOMICs.com/subscription Sign up for FREE Delivered right to your inbox!

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017